James Fox, MD
Pulmonary Disease · Tyler, TXNPI 1962602789
Payments from drug & device makers
Across 198 payments — averaging $29.45 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Intuitive Surgical$3K
- GSK$1K
- Boehringer Ingelheim$214
- AstraZeneca$178
- Johnson & Johnson$127
- Sanofi$125
- plus $1K from 27 others
What the payments were for
- Food & beverage$2,72347%
- Education$3,10753%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Intuitive Surgical | 1 | $3,000 |
| GSK | 99 | $1,102 |
| Boehringer Ingelheim | 11 | $214 |
| AstraZeneca | 12 | $178 |
| Johnson & Johnson(2 entities) | 3 | $127 |
| Sanofi | 5 | $125 |
| Actelion Pharmaceuticals US, Inc. | 2 | $117 |
| Takeda Pharmaceuticals U.S.A., Inc. | 7 | $111 |
| Paratek Pharmaceuticals, Inc. | 5 | $84 |
| Merck | 4 | $81 |
| Sunovion Pharmaceuticals Inc. | 12 | $80 |
| Pfizer | 4 | $66 |
| Electromed, Inc. | 4 | $51 |
| Grifols USA, LLC | 3 | $49 |
| Genentech USA, Inc. | 3 | $45 |
| Medtronic | 1 | $38 |
| Tactile Systems Technology Inc | 2 | $32 |
| Abiomed | 1 | $31 |
| Mylan Specialty L.p. | 2 | $30 |
| Beckman Coulter, Inc. | 1 | $27 |
| ANI Pharmaceuticals, Inc. | 1 | $25 |
| Regeneron Healthcare Solutions, Inc. | 1 | $24 |
| Viatris Specialty LLC | 1 | $24 |
| United Therapeutics Corporation | 1 | $21 |
| Teva Pharmaceuticals USA, Inc. | 1 | $20 |
| Hospira, Inc. | 1 | $18 |
| Pharming Healthcare, Inc. | 1 | $18 |
| Inogen, Inc. | 4 | $18 |
| Insmed, Inc. | 1 | $18 |
| Inspire Medical Systems, Inc. | 1 | $17 |
| Amgen | 1 | $17 |
| AbbVie | 1 | $14 |
| BTG International Inc. | 1 | $7 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- ION$3,000
How this compares
$5,830 in reported general payments places this provider in the 60th percentile of 904 pulmonary disease providers in Texas.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 436 | $310,554 |
| OfevNintedanib Esylate | 11 | $146,371 |
| XolairOmalizumab | 24 | $83,762 |
| Breo ElliptaFluticasone/Vilanterol | 144 | $64,693 |
| Breztri AerosphereBudesonide/Glycopyr/Formoterol | 56 | $43,199 |
| Anoro ElliptaUmeclidinium Brm/Vilanterol Tr | 50 | $28,262 |
| SymbicortBudesonide/Formoterol Fumarate | 47 | $19,968 |
| Stiolto RespimatTiotropium Br/Olodaterol Hcl | 38 | $17,988 |
| Combivent RespimatIpratropium/Albuterol Sulfate | 20 | $14,311 |
| Albuterol Sulfate HfaAlbuterol Sulfate | 320 | $10,500 |
| Bevespi AerosphereGlycopyrrolate/Formoterol Fum | 17 | $7,892 |
| Spiriva HandihalerTiotropium Bromide | 11 | $5,802 |
| Ventolin HfaAlbuterol Sulfate | 78 | $5,633 |
| Advair HfaFluticasone Propion/Salmeterol | 18 | $5,437 |
| Fluticasone-SalmeterolFluticasone Propion/Salmeterol | 26 | $4,830 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| GSKTrelegy Ellipta, Breo Ellipta, Anoro Ellipta | $1,102 | $403,509630 claims |
| Boehringer IngelheimOfev, Stiolto Respimat, Combivent Respimat | $214 | $178,67169 claims |
| AstraZenecaBreztri Aerosphere, Symbicort, Bevespi Aerosphere | $178 | $71,060120 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 60th percentile of 904 pulmonary disease providers in Texas.
Other pulmonary disease in Tyler
- Julie PhilleyTyler$2.4M
- Pamela McShaneTyler$1.4M
- Megan DevineTyler$309K
- Charles AndrewsSan Antonio$17M
- Ivan RosasHouston$13.8M
- Shahrukh KureishyMcKinney$12.4M
- Raksha JainDallas$3.4M
- Kelly ChinDallas$2.7M
- Nicola HananiaHouston$2.2M
- Sandeep SahayHouston$2.1M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.